A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 5,400 shares of ALLO stock, worth $10,098. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,400
Previous 13,700 60.58%
Holding current value
$10,098
Previous $31,000 51.61%
% of portfolio
0.0%
Previous 0.0%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$2.08 - $3.5 $5.39 Million - $9.08 Million
2,593,091 Added 105.99%
5,039,594 $14.1 Million
Q2 2024

Aug 14, 2024

SELL
$2.23 - $4.38 $1.49 Million - $2.92 Million
-666,722 Reduced 21.42%
2,446,503 $5.7 Million
Q1 2024

May 15, 2024

SELL
$2.92 - $5.63 $2.74 Million - $5.29 Million
-940,001 Reduced 23.19%
3,113,225 $13.9 Million
Q4 2023

Feb 14, 2024

SELL
$2.28 - $3.5 $142,281 - $218,414
-62,404 Reduced 1.52%
4,053,226 $13 Million
Q3 2023

Nov 14, 2023

SELL
$3.17 - $5.96 $1.98 Million - $3.72 Million
-624,711 Reduced 13.18%
4,115,630 $13 Million
Q2 2023

Aug 14, 2023

BUY
$4.53 - $6.74 $1.78 Million - $2.64 Million
391,838 Added 9.01%
4,740,341 $23.6 Million
Q1 2023

May 15, 2023

BUY
$4.92 - $8.21 $18.7 Million - $31.3 Million
3,808,199 Added 704.83%
4,348,503 $21.5 Million
Q4 2022

Feb 14, 2023

SELL
$5.62 - $11.11 $1.98 Million - $3.92 Million
-352,551 Reduced 39.49%
540,304 $3.4 Million
Q3 2022

Nov 14, 2022

BUY
$10.32 - $17.28 $8.37 Million - $14 Million
811,492 Added 997.37%
892,855 $9.64 Million
Q2 2022

Aug 15, 2022

SELL
$6.78 - $12.28 $17.2 Million - $31.1 Million
-2,534,748 Reduced 96.89%
81,363 $927,000
Q1 2022

May 16, 2022

BUY
$7.65 - $15.29 $1.85 Million - $3.69 Million
241,614 Added 10.18%
2,616,111 $23.8 Million
Q4 2021

Feb 14, 2022

BUY
$13.13 - $24.52 $27.1 Million - $50.6 Million
2,064,988 Added 667.18%
2,374,497 $35.4 Million
Q3 2021

Nov 15, 2021

SELL
$21.01 - $27.64 $2.13 Million - $2.8 Million
-101,301 Reduced 24.66%
309,509 $7.95 Million
Q2 2021

Aug 16, 2021

BUY
$23.49 - $35.8 $8.91 Million - $13.6 Million
379,323 Added 1204.7%
410,810 $10.7 Million
Q1 2021

May 17, 2021

SELL
$25.79 - $39.02 $7.02 Million - $10.6 Million
-272,366 Reduced 89.64%
31,487 $1.11 Million
Q4 2020

Feb 16, 2021

BUY
$25.24 - $43.45 $6.07 Million - $10.4 Million
240,364 Added 378.59%
303,853 $7.67 Million
Q3 2020

Nov 16, 2020

SELL
$32.38 - $44.96 $1.1 Million - $1.52 Million
-33,851 Reduced 34.78%
63,489 $2.39 Million
Q2 2020

Aug 14, 2020

BUY
$18.39 - $54.04 $773,373 - $2.27 Million
42,054 Added 76.07%
97,340 $4.17 Million
Q1 2020

May 15, 2020

SELL
$18.22 - $28.25 $17,491 - $27,120
-960 Reduced 1.71%
55,286 $1.07 Million
Q4 2019

Feb 14, 2020

SELL
$24.82 - $31.4 $7.34 Million - $9.28 Million
-295,648 Reduced 84.02%
56,246 $1.46 Million
Q3 2019

Nov 14, 2019

SELL
$26.11 - $32.99 $2.39 Million - $3.02 Million
-91,683 Reduced 20.67%
351,894 $9.59 Million
Q2 2019

Aug 14, 2019

SELL
$25.56 - $31.09 $5.65 Million - $6.87 Million
-220,926 Reduced 33.25%
443,577 $11.9 Million
Q1 2019

May 15, 2019

BUY
$24.82 - $32.54 $7.29 Million - $9.56 Million
293,885 Added 79.3%
664,503 $0
Q4 2018

Feb 14, 2019

BUY
$22.5 - $33.3 $8.34 Million - $12.3 Million
370,618 New
370,618 $9.98 Million

Others Institutions Holding ALLO

About Allogene Therapeutics, Inc.


  • Ticker ALLO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 143,807,008
  • Market Cap $269M
  • Description
  • Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...
More about ALLO
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.